CTLA-4, also known as CD152, is the first detected co-inhibitory checkpoint receptor (ICR) that normally expressed on T cells and is linked to the suppression of endogenous anti-tumor immunity mediated by T cells [27, 28]. The gene discussed is CTLA4; the disease is neoplasm.